Prestige Consumer Healthcare (NYSE:PBH) Upgraded by Zacks Research to “Hold” Rating

Prestige Consumer Healthcare (NYSE:PBH) was upgraded by research analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a report issued on Monday,Zacks.com reports.

Other research analysts have also issued research reports about the company. Oppenheimer lowered Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a research report on Thursday, May 14th. Weiss Ratings cut Prestige Consumer Healthcare from a “hold (c-)” rating to a “sell (d+)” rating in a report on Thursday, June 25th. Finally, Canaccord Genuity Group cut their target price on Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating on the stock in a research report on Friday, May 15th. Two research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $70.75.

Prestige Consumer Healthcare Stock Performance

NYSE:PBH opened at $53.57 on Monday. The company has a market cap of $2.54 billion, a price-to-earnings ratio of 15.00, a PEG ratio of 1.66 and a beta of 0.34. Prestige Consumer Healthcare has a 1 year low of $42.62 and a 1 year high of $71.07. The stock’s 50 day simple moving average is $49.11 and its two-hundred day simple moving average is $55.82. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.23 and a quick ratio of 1.99.

Prestige Consumer Healthcare (NYSE:PBH) last posted its earnings results on Thursday, August 6th. The company reported $0.98 EPS for the quarter, beating analysts’ consensus estimates of $0.89 by $0.09. Prestige Consumer Healthcare had a return on equity of 11.39% and a net margin of 15.57%.The firm had revenue of $265.71 million during the quarter, compared to the consensus estimate of $253.02 million. During the same period in the prior year, the company earned $0.90 EPS. The company’s quarterly revenue was up 6.5% compared to the same quarter last year. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.550-4.650 EPS. As a group, equities analysts anticipate that Prestige Consumer Healthcare will post 4.55 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of PBH. Massachusetts Financial Services Co. MA grew its position in Prestige Consumer Healthcare by 10.2% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 650,793 shares of the company’s stock valued at $40,147,000 after acquiring an additional 60,496 shares during the last quarter. Leeward Investments LLC MA lifted its position in shares of Prestige Consumer Healthcare by 23.3% during the fourth quarter. Leeward Investments LLC MA now owns 387,321 shares of the company’s stock worth $23,894,000 after purchasing an additional 73,162 shares during the last quarter. Legato Capital Management LLC lifted its position in shares of Prestige Consumer Healthcare by 532.4% during the fourth quarter. Legato Capital Management LLC now owns 27,774 shares of the company’s stock worth $1,713,000 after purchasing an additional 23,382 shares during the last quarter. Brandes Investment Partners LP boosted its stake in shares of Prestige Consumer Healthcare by 93.2% during the fourth quarter. Brandes Investment Partners LP now owns 606,737 shares of the company’s stock valued at $37,430,000 after purchasing an additional 292,744 shares during the period. Finally, Bessemer Group Inc. boosted its stake in shares of Prestige Consumer Healthcare by 20.9% during the first quarter. Bessemer Group Inc. now owns 374,691 shares of the company’s stock valued at $22,207,000 after purchasing an additional 64,760 shares during the period. Institutional investors own 99.95% of the company’s stock.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).